https://trial.medpath.com/news/fda-approves-pembrolizumab-for-advanced-esophageal-squamous-cell-cancer-with-pd-l1-expression 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pembrolizumab-for-advanced-esophageal-squamous-cell-cancer-with-pd-l1-expression 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regional-chemotherapy-for-liver-metastases-of-colorectal-cancer-shows-varied-perfusion-patterns 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regional-chemotherapy-for-liver-metastases-of-colorectal-cancer-shows-varied-perfusion-patterns 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/regional-chemotherapy-shows-promise-in-treating-colorectal-cancer-metastatic-to-the-liver 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regional-chemotherapy-shows-promise-in-treating-colorectal-cancer-metastatic-to-the-liver 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/d3bio-s-novel-kras-g12c-inhibitor-shows-promising-results-in-phase-1-cancer-trial 2010-01-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/d3bio-s-novel-kras-g12c-inhibitor-shows-promising-results-in-phase-1-cancer-trial 2010-01-01T00:00:00+00:00 weekly 0.7